US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Emera Inc.

49.19

-0.2900-0.59%

Post-market: 49.190.00000.00%19:30 EDT

Volume:322.54K

Turnover:15.89M

Market Cap:15.04B

PE:22.06

High:49.58

Open:49.49

Low:49.03

Close:49.48

52wk High:55.49

52wk Low:45.77

Shares:305.78M

Float Shares:305.78M

Volume Ratio:0.65

T/O Rate:0.11%

Dividend:2.11

Dividend Rate:4.29%

EPS(TTM):2.23

EPS(LYR):2.47

ROE:7.56%

ROA:2.91%

PB:1.61

PE(LYR):19.95

Loading ...

Overview Company News Filings

Oral Infigratinib Shows Meaningful Benefits Beyond Growth Within 52 Weeks in Children with Achondroplasia in the Phase 3 PROPEL 3 Trial

Press Release: Can-Fite Reports Q2 2026 Financial Results and Ongoing Clinical Progress Highlighting Longer-than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study

Emera (EMA) Gets a Hold from J.P. Morgan

Acoramidis Demonstrates Reversal of Cardiac Structural Disease Progression and Functional Decline and Significantly Increases Days Alive and Free from Hospitalization in ATTR-CM

Japan Breakthrough Hands Shiba Inu (SHIB) Big Win in August, but September Threat Looms

U.S. FDA Approves Revolution Medicines’ RASONQUE™ (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer

BridgeBio to Present New Acoramidis Data from Open-Label Extension Analyses in ATTR-CM at ESC Congress 2026

First Patient Treated in PIONEER-1 Registrational Trial of Privosegtor for Optic Neuritis

Analysts Offer Insights on Utilities Companies: Emera (EMA) and Duke Energy (DUK)

Zcash (ZEC) Breaks Out Unexpectedly as Key Golden EMA Cross Occurs

Press Release: Lantern Pharma Reports Second Quarter 2026 Financial Results and Provides Business Update

Sasseur REIT's 1HFY2026 DPU up 10% y-o-y to 3.366 cents

Press Release: Zenas BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Press Release: Valneva Reports Half Year 2026 Financial Results and Provides Corporate Updates

Press Release: Longeveron Announces 2026 Second Quarter Financial Results and Provides Business Update

Press Release: Bernhard Capital Partners Completes Acquisition of New Mexico Gas Company

Milestone Pharmaceuticals Announces Second Quarter 2026 Financial Results and Provides Corporate Update

Press Release: Pharvaris Reports Second Quarter 2026 Financial Results and Provides Business Update

Analysts Are Bullish on These Utilities Stocks: Emera (EMA), Edenor SA (EDN)

Press Release: Theriva(TM) Biologics Reports Second Quarter 2026 Operational Highlights and Financial Results

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrnest.com/stock/EMA/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"EMA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EMA\",,,,,undefined,":{"symbol":"EMA","market":"US","secType":"STK","nameCN":"Emera Inc.","latestPrice":49.19,"timestamp":1789156800000,"preClose":49.48,"halted":0,"volume":322535,"hourTrading":{"tag":"盘后","latestPrice":49.19,"preClose":49.19,"latestTime":"19:30 EDT","volume":114920,"amount":5650342.26916,"timestamp":1789169408200,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.005860953920776055,"floatShares":305783111,"shares":305783111,"eps":2.229761,"marketStatus":"Closed","change":-0.29,"latestTime":"09-11 16:00:00 EDT","open":49.49,"high":49.58,"low":49.03,"amount":15887316.78782,"amplitude":0.011116,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":2.229761,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1789372800000},"marketStatusCode":5,"adr":0,"exchange":"NYSE","adjPreClose":49.48,"dividendRate":0.04287,"postHourTrading":{"tag":"盘后","latestPrice":49.19,"preClose":49.19,"latestTime":"19:30 EDT","volume":114920,"amount":5650342.26916,"timestamp":1789169408200,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.654959,"impliedVol":0.3093,"impliedVolPercentile":0.8884},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EMA\",,,,,undefined,":{"symbol":"EMA","floatShares":305783111,"roa":"2.91%","roe":"7.56%","lyrEps":2.465138,"volumeRatio":0.654959,"shares":305783111,"dividePrice":2.108663,"high":49.58,"amplitude":0.011116,"preClose":49.48,"low":49.03,"week52Low":45.77,"pbRate":"1.61","psRate":"2.33","week52High":55.49,"institutionHeld":0,"latestPrice":49.19,"eps":2.229761,"divideRate":0.042868,"volume":322535,"delay":0,"ttmEps":2.229761,"open":49.49,"prevYearClose":49.24,"prevWeekClose":50.35,"prevMonthClose":50.09,"prevQuarterClose":53.02,"fiveDayClose":50.3,"twentyDayClose":51.34,"sixtyDayClose":52.55,"dividendPayoutRate":0.8394110571990734,"dividendFrequency":"Q","dividendGrowthYears":0,"fiveYearAvgDividendRate":0.04206805783252231},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/EMA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-07","symbol":"EMA","fiscalQuarterEnding":"2026/06","expectedEps":0.51,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1786075200000,"reportTimeType":"pre","actualEps":0.5},{"date":"2026-08-03","symbol":"EMA","amount":0.7325,"announcedDate":"2026-07-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-08-03","defaultRemindTime":1785763800000,"name":"Emera Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-08-17","payableDate":"2026-08-03","currency":"CAD","dateTimestamp":1785729600000,"payDate":"2026-08-17"},{"market":"US","date":"2026-05-08","symbol":"EMA","fiscalQuarterEnding":"2026/03","expectedEps":0.89,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1778212800000,"reportTimeType":"pre","actualEps":1},{"date":"2026-05-01","symbol":"EMA","amount":0.7325,"announcedDate":"2026-04-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-05-01","defaultRemindTime":1777642200000,"name":"Emera Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-05-15","payableDate":"2026-05-01","currency":"CAD","dateTimestamp":1777608000000,"payDate":"2026-05-15"},{"market":"US","date":"2026-02-23","symbol":"EMA","fiscalQuarterEnding":"2025/12","expectedEps":0.43,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1771822800000,"reportTimeType":"pre","actualEps":0.4}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"EMA\",market:\"US\",,,undefined,":[{"executeDate":"2016-10-28","recordDate":"2016-11-01","paymentDate":"2016-11-15","value":0.3880294,"currency":"USD"},{"executeDate":"2025-08-01","recordDate":"2025-08-01","paymentDate":"2025-08-15","value":0.725,"currency":"CAD"},{"executeDate":"2025-10-31","recordDate":"2025-10-31","paymentDate":"2025-11-14","value":0.7325,"currency":"CAD"},{"executeDate":"2026-01-30","recordDate":"2026-01-30","paymentDate":"2026-02-13","value":0.7325,"currency":"CAD"},{"executeDate":"2026-05-01","recordDate":"2026-05-01","paymentDate":"2026-05-15","value":0.7325,"currency":"CAD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"EMA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0,"hold":1,"sell":0,"strongSell":0,"meanLabel":"HOLD","meanPercent":1,"analysts":1,"updateTime":1778299200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/EMA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"EMA","date":"2026-09-10","current":22.06066,"percent":0.646875,"low":16.637027,"twenty":17.67073,"median":20.281209,"eighty":21.0432,"high":22.07626,"avg":19.824489,"sd":1.480286,"marketCap":15477268878.68},"quantilePoints":[{"date":"2025-05-30","current":19.76944,"twenty":19.76944,"median":19.76944,"eighty":19.76944,"marketCap":13505496352.43},{"date":"2025-06-06","current":19.324012,"twenty":19.535669,"median":19.692043,"eighty":19.76944,"marketCap":13350532994.37},{"date":"2025-06-13","current":19.308216,"twenty":19.137627,"median":19.324012,"eighty":19.722054,"marketCap":13371262392.6},{"date":"2025-06-20","current":19.245035,"twenty":19.160372,"median":19.387193,"eighty":19.674036,"marketCap":13211518175.96},{"date":"2025-06-27","current":19.308216,"twenty":19.224185,"median":19.382455,"eighty":19.560942,"marketCap":13348226238.04},{"date":"2025-07-03","current":19.469329,"twenty":19.242508,"median":19.399829,"eighty":19.679723,"marketCap":13533023992.92},{"date":"2025-07-11","current":19.753645,"twenty":19.282944,"median":19.43142,"eighty":19.706259,"marketCap":13611556279.78},{"date":"2025-07-18","current":19.592532,"twenty":19.308216,"median":19.502499,"eighty":19.712577,"marketCap":13439260670.95},{"date":"2025-07-25","current":20.116937,"twenty":19.317694,"median":19.614646,"eighty":19.767545,"marketCap":13920070443.21},{"date":"2025-08-01","current":20.552889,"twenty":19.356234,"median":19.663612,"eighty":19.931816,"marketCap":14004388886.88},{"date":"2025-08-08","current":20.884591,"twenty":19.383402,"median":19.706259,"eighty":20.124519,"marketCap":14315223696.17},{"date":"2025-08-15","current":20.686356,"twenty":19.389088,"median":19.714157,"eighty":20.375981,"marketCap":14241020029.57},{"date":"2025-08-22","current":21.111677,"twenty":19.401724,"median":19.753645,"eighty":20.511821,"marketCap":14434555399.62},{"date":"2025-08-29","current":20.468969,"twenty":19.420679,"median":19.785235,"eighty":20.581071,"marketCap":14130173597.74},{"date":"2025-09-05","current":20.484722,"twenty":19.429525,"median":19.883167,"eighty":20.585711,"marketCap":14060435241.25},{"date":"2025-09-12","current":20.283088,"twenty":19.441529,"median":20.015847,"eighty":20.549566,"marketCap":13928376571.28},{"date":"2025-09-19","current":19.923928,"twenty":19.461747,"median":20.073945,"eighty":20.542062,"marketCap":13714455884.59},{"date":"2025-09-26","current":20.585539,"twenty":19.495865,"median":20.087756,"eighty":20.542062,"marketCap":14040465233.16},{"date":"2025-10-03","current":21.108526,"twenty":19.558414,"median":20.183278,"eighty":20.617044,"marketCap":14341364686.36},{"date":"2025-10-10","current":21.127429,"twenty":19.601378,"median":20.281209,"eighty":20.758818,"marketCap":14318469638.17},{"date":"2025-10-17","current":21.666169,"twenty":19.623491,"median":20.300416,"eighty":20.797254,"marketCap":14653790731.95},{"date":"2025-10-24","current":21.757535,"twenty":19.646868,"median":20.374454,"eighty":20.916344,"marketCap":14770054950.94},{"date":"2025-10-31","current":21.360568,"twenty":19.663296,"median":20.386244,"eighty":21.06631,"marketCap":14513331426.12},{"date":"2025-11-07","current":21.272354,"twenty":19.674036,"median":20.41226,"eighty":21.097184,"marketCap":14296037747.86},{"date":"2025-11-14","current":17.374062,"twenty":19.601378,"median":20.386244,"eighty":21.06631,"marketCap":14568586353.81},{"date":"2025-11-21","current":17.212836,"twenty":19.441529,"median":20.374454,"eighty":21.041735,"marketCap":14368588864.66},{"date":"2025-11-28","current":17.407331,"twenty":19.394143,"median":20.301992,"eighty":21.030393,"marketCap":14577653448.13},{"date":"2025-12-05","current":16.921093,"twenty":19.311375,"median":20.282148,"eighty":21.003928,"marketCap":14257439118.84},{"date":"2025-12-12","current":16.693329,"twenty":19.18059,"median":20.230664,"eighty":20.983135,"marketCap":14234564864},{"date":"2025-12-19","current":17.167393,"twenty":17.900621,"median":20.102346,"eighty":20.957301,"marketCap":14657419004.37},{"date":"2025-12-26","current":17.216186,"twenty":17.458514,"median":20.073945,"eighty":20.944699,"marketCap":14789996894.17},{"date":"2026-01-02","current":17.370269,"twenty":17.373303,"median":20.0392,"eighty":20.932097,"marketCap":14871263471.89},{"date":"2026-01-09","current":17.43447,"twenty":17.368214,"median":19.923928,"eighty":20.903742,"marketCap":14773589152.84},{"date":"2026-01-16","current":17.439606,"twenty":17.353836,"median":19.83736,"eighty":20.887161,"marketCap":14748903694.51},{"date":"2026-01-23","current":17.57828,"twenty":17.358457,"median":19.76786,"eighty":20.862056,"marketCap":14967122519.73},{"date":"2026-01-30","current":17.452446,"twenty":17.36616,"median":19.731531,"eighty":20.822459,"marketCap":15149245081.41},{"date":"2026-02-06","current":17.639913,"twenty":17.358457,"median":19.706259,"eighty":20.792844,"marketCap":15150466223.22},{"date":"2026-02-13","current":17.632209,"twenty":17.329694,"median":19.687304,"eighty":20.780241,"marketCap":15197950382.19},{"date":"2026-02-20","current":18.01228,"twenty":17.336884,"median":19.662032,"eighty":20.776461,"marketCap":15461241242.05},{"date":"2026-02-27","current":19.370854,"twenty":17.349212,"median":19.603589,"eighty":20.77079,"marketCap":15419204876.87},{"date":"2026-03-06","current":19.860551,"twenty":17.357687,"median":19.614646,"eighty":20.758818,"marketCap":15772457447.89},{"date":"2026-03-13","current":20.172176,"twenty":17.364105,"median":19.663612,"eighty":20.731723,"marketCap":16126249798.12},{"date":"2026-03-20","current":19.982975,"twenty":17.371786,"median":19.706259,"eighty":20.697698,"marketCap":15868293252.05},{"date":"2026-03-27","current":19.866116,"twenty":17.374599,"median":19.676248,"eighty":20.661152,"marketCap":15623406729.11},{"date":"2026-04-02","current":20.186088,"twenty":17.375919,"median":19.706259,"eighty":20.620195,"marketCap":15797694590.77},{"date":"2026-04-10","current":20.433719,"twenty":17.383333,"median":19.710303,"eighty":20.603182,"marketCap":16095943521.79},{"date":"2026-04-17","current":20.225489,"twenty":17.405284,"median":19.739002,"eighty":20.583555,"marketCap":16062393790.34},{"date":"2026-04-24","current":20.11598,"twenty":17.412759,"median":19.756565,"eighty":20.571074,"marketCap":16011506016.84},{"date":"2026-05-01","current":20.349038,"twenty":17.435497,"median":19.769087,"eighty":20.551228,"marketCap":16279588937.86},{"date":"2026-05-08","current":20.003663,"twenty":17.442174,"median":19.801031,"eighty":20.543322,"marketCap":15972071463.03},{"date":"2026-05-15","current":20.526748,"twenty":17.453473,"median":19.863334,"eighty":20.551228,"marketCap":15993082457.11},{"date":"2026-05-22","current":20.821212,"twenty":17.457768,"median":19.873689,"eighty":20.574777,"marketCap":16159791825.34},{"date":"2026-05-29","current":20.784047,"twenty":17.458514,"median":19.874498,"eighty":20.606796,"marketCap":16109213261.77},{"date":"2026-06-05","current":20.455276,"twenty":17.46015,"median":19.931505,"eighty":20.606796,"marketCap":15744335184.44},{"date":"2026-06-12","current":20.798341,"twenty":17.481546,"median":19.990575,"eighty":20.612514,"marketCap":15890994194.64},{"date":"2026-06-18","current":20.901261,"twenty":17.493192,"median":20.015847,"eighty":20.650154,"marketCap":15823421326.33},{"date":"2026-06-26","current":21.595968,"twenty":17.496103,"median":20.061717,"eighty":20.767009,"marketCap":16281617755.86},{"date":"2026-07-02","current":21.507343,"twenty":17.504259,"median":20.064683,"eighty":20.784032,"marketCap":16222688501.02},{"date":"2026-07-10","current":21.544508,"twenty":17.526194,"median":20.082188,"eighty":20.821212,"marketCap":16271827884.13},{"date":"2026-07-17","current":21.936175,"twenty":17.541814,"median":20.087829,"eighty":20.898969,"marketCap":16718811747.19},{"date":"2026-07-24","current":22.07626,"twenty":17.564926,"median":20.116937,"eighty":20.951,"marketCap":16761941188.16},{"date":"2026-07-31","current":21.66744,"twenty":17.586675,"median":20.124404,"eighty":21.004011,"marketCap":16545696607.24},{"date":"2026-08-07","current":20.666833,"twenty":17.604226,"median":20.156816,"eighty":21.026741,"marketCap":15758445214.07},{"date":"2026-08-14","current":21.122954,"twenty":17.619883,"median":20.180562,"eighty":21.040346,"marketCap":15758083883.88},{"date":"2026-08-21","current":21.131815,"twenty":17.635291,"median":20.20188,"eighty":21.05159,"marketCap":15955602988.26},{"date":"2026-08-28","current":20.499692,"twenty":17.645049,"median":20.225489,"eighty":21.044992,"marketCap":15379168560.24},{"date":"2026-09-04","current":20.473108,"twenty":17.659944,"median":20.257815,"eighty":21.043803,"marketCap":15442660903.12},{"date":"2026-09-10","current":20.564677,"twenty":17.67073,"median":20.281209,"eighty":21.0432,"marketCap":15477268878.68}],"updateTime":1789178039505},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"EMA\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2666585879","title":"Oral Infigratinib Shows Meaningful Benefits Beyond Growth Within 52 Weeks in Children with Achondroplasia in the Phase 3 PROPEL 3 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2666585879","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666585879?lang=en_us&edition=fundamental","pubTime":"2026-09-09 16:00","pubTimestamp":1788940800,"startTime":"0","endTime":"0","summary":"- Treatment with oral infigratinib for 52 weeks in PROPEL 3 resulted in favorable trends against placebo in clinically meaningful exploratory endpoints including sleep apnea and otitis media events St","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/09/3358343/0/en/oral-infigratinib-shows-meaningful-benefits-beyond-growth-within-52-weeks-in-children-with-achondroplasia-in-the-phase-3-propel-3-trial.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AHI","BK4081","BK4097","BK4588","BK4156","EMA","MAA","BK4167","BK4585","BK4215","SPRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665320770","title":"Press Release: Can-Fite Reports Q2 2026 Financial Results and Ongoing Clinical Progress Highlighting Longer-than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2665320770","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665320770?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:20","pubTimestamp":1788870000,"startTime":"0","endTime":"0","summary":"RAMAT GAN, Israel, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company developing a pipeline of proprietary small molecule drugs targ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4006","CANF","PRGS","EMA","LU2065732104.USD","COAL","BK4139","BK4097","HCC","BK4081"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664811530","title":"Emera (EMA) Gets a Hold from J.P. Morgan","url":"https://stock-news.laohu8.com/highlight/detail?id=2664811530","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664811530?lang=en_us&edition=fundamental","pubTime":"2026-09-02 20:18","pubTimestamp":1788351522,"startTime":"0","endTime":"0","summary":"J.P. Morgan analyst Eli Jossen maintained a Hold rating on Emera yesterday and set a price target of C$75.00. The company’s shares closed yesterday...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/emera-ema-gets-a-hold-from-j-p-morgan-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/emera-ema-gets-a-hold-from-j-p-morgan-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4516","LU0390134368.USD","LU2487616109.SGD","LU1989772923.USD","LU2023251221.USD","LU1548497426.USD","LU2111349929.HKD","BK4581","LU1064131342.USD","LU2357305700.SGD","LU0795875169.SGD","LU0912757837.SGD","LU2089284900.SGD","EMA","BK4534","IAI","LU1074936037.SGD","BK4585","LU1720051108.HKD","BK4588","LU2271345857.HKD","LU0528227936.USD","LU1989772840.SGD","LU1162221912.USD","IE00BZ1G4Q59.USD","LU1791710400.SGD","BK4081","LU2028103732.USD","LU0225283273.USD","LU0234570918.USD","IE00B775SV38.USD","KBWB","LU0882574139.USD","LU1732800096.USD","LU1244550221.USD","LU0795875086.SGD","LU0320765646.SGD","LU1988902786.USD","LU0106831901.USD","LU1732799900.SGD","LU1668664300.SGD","LU0267386448.USD","LU0557290698.USD","LU2347655156.SGD","LU0158827948.USD","LU2133065610.SGD","LU0210528500.USD","LU1244550577.SGD","LU1244550494.USD","IE00BKVL7J92.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663004445","title":"Acoramidis Demonstrates Reversal of Cardiac Structural Disease Progression and Functional Decline and Significantly Increases Days Alive and Free from Hospitalization in ATTR-CM","url":"https://stock-news.laohu8.com/highlight/detail?id=2663004445","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663004445?lang=en_us&edition=fundamental","pubTime":"2026-08-30 22:00","pubTimestamp":1788098400,"startTime":"0","endTime":"0","summary":"- Acoramidis is the first therapy shown to potentially reverse cardiac structural disease progression and functional decline through 42 months based on CMR imaging,with up to half of patients showing ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/30/3352965/0/en/acoramidis-demonstrates-reversal-of-cardiac-structural-disease-progression-and-functional-decline-and-significantly-increases-days-alive-and-free-from-hospitalization-in-attr-cm.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4081","AIPO","QTOC","LU2360107325.USD","AGIX","BK4139","CVM","BK4129","LU1939255532.USD","LU0124676726.USD","LU2244417387.USD","VTHR","ARTY","LU2308191902.HKD","CHAT","EMA","LU2238339852.HKD","LU0187121727.USD","LU0689626769.HKD","LU2298064838.USD","BK4516","ACM","LU1861214812.USD","ATTR","LU1861219969.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662009803","title":"Japan Breakthrough Hands Shiba Inu (SHIB) Big Win in August, but September Threat Looms","url":"https://stock-news.laohu8.com/highlight/detail?id=2662009803","media":"utoday","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662009803?lang=en_us&edition=fundamental","pubTime":"2026-08-27 12:40","pubTimestamp":1787805600,"startTime":"0","endTime":"0","summary":"TheShiba Inu (SHIB) meme token is ending the month with an all-time record August return, confirming a break in its long-term downtrend. However, the asset's historical vulnerability to September seas","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"utodaynews_highlight","url":"https://u.today/japan-breakthrough-hands-shiba-inu-shib-big-win-in-august-but-september-threat-looms","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://u.today/japan-breakthrough-hands-shiba-inu-shib-big-win-in-august-but-september-threat-looms","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"utodaynews_highlight","symbols":["EMA","BK4081","FSA.AU","BK7129","BK7093","EMA.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662759746","title":"U.S. FDA Approves Revolution Medicines’ RASONQUE™ (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2662759746","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662759746?lang=en_us&edition=fundamental","pubTime":"2026-08-27 00:59","pubTimestamp":1787763540,"startTime":"0","endTime":"0","summary":"RASONQUE is indicated for the treatment of adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent syste","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/26/3351615/0/en/u-s-fda-approves-revolution-medicines-rasonque-daraxonrasib-the-first-broad-ras-targeted-medicine-in-metastatic-pancreatic-cancer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BJJMRZ35.SGD","IE00B4R5TH58.HKD","LU1861219969.SGD","LU2360107325.USD","BK4141","LU1861220033.SGD","RVMD","IE0002141913.USD","LU0889565916.HKD","IE00BD6J9T35.USD","ITT","LU0724618433.USD","BK4512","BK4613","SRET","LU0210528500.USD","ONG","BK4023","BK4605","BBH","PTH","LU1854103824.USD","BK4585","LU0053671581.USD","HR","IE00B2B36J28.USD","LU0109394709.USD","ON","TTD","CANC","LU1978683503.SGD","PFS","LU2487616109.SGD","LU1720051017.SGD","LU1720051108.HKD","IE00BZ199S13.USD","TTDU","LABU","BK4139","L","LU0320765992.SGD","ONX","BK4588","IE0009354923.USD","LU0124384867.USD","BK4009","EMA","IE0009355771.USD","BK4225","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661275001","title":"BridgeBio to Present New Acoramidis Data from Open-Label Extension Analyses in ATTR-CM at ESC Congress 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2661275001","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661275001?lang=en_us&edition=fundamental","pubTime":"2026-08-24 19:30","pubTimestamp":1787571000,"startTime":"0","endTime":"0","summary":"PALO ALTO, Calif., Aug.  24, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic cond","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/24/3349646/0/en/bridgebio-to-present-new-acoramidis-data-from-open-label-extension-analyses-in-attr-cm-at-esc-congress-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EMA","BK4207","ATTR","BK4081","CM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661022177","title":"First Patient Treated in PIONEER-1 Registrational Trial of Privosegtor for Optic Neuritis","url":"https://stock-news.laohu8.com/highlight/detail?id=2661022177","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661022177?lang=en_us&edition=fundamental","pubTime":"2026-08-24 16:00","pubTimestamp":1787558400,"startTime":"0","endTime":"0","summary":"The PIONEER program marks a key step toward potential first-in-class neuroprotection for optic neuritis and other neurological diseases, supported by positive Acuity Phase 2 data, FDA Breakthrough The","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/24/3349489/0/en/first-patient-treated-in-pioneer-1-registrational-trial-of-privosegtor-for-optic-neuritis.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2298322129.HKD","ON","LU1854103824.USD","LU0225283273.USD","LU0053666078.USD","LU2089284900.SGD","LU0267386448.USD","BK4504","BK4081","BK4588","LU0390134368.USD","IE00B3S45H60.SGD","IAI","LU0348723411.USD","LU1983260115.SGD","LU1861220033.SGD","LU1074936037.SGD","BK4581","LU2028103732.USD","LU0724618433.USD","KBWB","LU0882574139.USD","BK4141","LU1732799900.SGD","BK4127","LU1732800096.USD","ONG","LU0528227936.USD","LABU","LU2089283258.USD","LU1791710582.SGD","LU1978683503.SGD","LU0158827948.USD","LU2347655156.SGD","IE00BZ1G4Q59.USD","ONX","EMA","LU1244550221.USD","LU0098860793.USD","LU1720051017.SGD","LU0106261372.USD","LU0795875086.SGD","LU1989772923.USD","IE00BD6J9T35.USD","LU0234570918.USD","LU0912757837.SGD","LU1668664300.SGD","LU1244550494.USD","IE00BZ199S13.USD","IE00B775SV38.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661665992","title":"Analysts Offer Insights on Utilities Companies: Emera (EMA) and Duke Energy (DUK)","url":"https://stock-news.laohu8.com/highlight/detail?id=2661665992","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661665992?lang=en_us&edition=fundamental","pubTime":"2026-08-21 17:00","pubTimestamp":1787302851,"startTime":"0","endTime":"0","summary":"Companies in the Utilities sector have received a lot of coverage today as analysts weigh in on Emera (EMA) and Duke Energy (DUK). Emera (EMA) In a...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-utilities-companies-emera-ema-and-duke-energy-duk-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-utilities-companies-emera-ema-and-duke-energy-duk-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2362541513.USD","LU1244550577.SGD","BK4585","BK4081","LU1621767737.EUR","JXI","BK4588","IDU","IE00B29SXK94.USD","LU2362540622.SGD","XLU","BK4566","URAN","LU2362541273.HKD","LU2384288077.EUR","IE000M9KFDE8.USD","LU1621768206.USD","LU1430594728.SGD","VPU","FPWR","TRUU","LU1585245621.USD","EMA","LU1244550221.USD","BK4606","DUK","UPW","LU2463526074.USD","IE00B29SXL02.USD","FUTY","NUKX","LU1621767810.EUR","LU1621768115.EUR","LU1244550494.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660249644","title":"Zcash (ZEC) Breaks Out Unexpectedly as Key Golden EMA Cross Occurs","url":"https://stock-news.laohu8.com/highlight/detail?id=2660249644","media":"utoday","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660249644?lang=en_us&edition=fundamental","pubTime":"2026-08-18 08:00","pubTimestamp":1787011200,"startTime":"0","endTime":"0","summary":"As a significant bullish technical signal forms beneath the price Zcash is trying to break out of its recent consolidation. While ZEC's shorter-term moving averages have converged around $495 and are ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"utodaynews_highlight","url":"https://u.today/zcash-zec-breaks-out-unexpectedly-as-key-golden-ema-cross-occurs","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://u.today/zcash-zec-breaks-out-unexpectedly-as-key-golden-ema-cross-occurs","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"utodaynews_highlight","symbols":["EMA","BK4081"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659450691","title":"Press Release: Lantern Pharma Reports Second Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2659450691","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659450691?lang=en_us&edition=fundamental","pubTime":"2026-08-14 19:30","pubTimestamp":1786707000,"startTime":"0","endTime":"0","summary":"Open Medicine AI Established as a Separate Company with Executed Commercial Licenses; Progression-Free Survival Benefit Deepens in EGFR Exon 21 L858R Lung Cancer with LP-300; EMA Clears LP-184, zirdafulven, for Biomarker-Selected Bladder Cancer Trial; LP-184 Development Positioned to Advance in Multiple Indications including Triple Negative Breast Cancer and Pediatric Brain Cancers--  Open Medicine AI  established as a separate company with. withZeta.ai. OMAI is currently wholly owned by Lantern and intends to. raise capital at the OMAI level. A dedicated OMAI informational call is. planned for mid-September 2026 to detail the market opportunity, platform. --  LP-300 -- HARMONIC benefit deepens with treatment duration in. emerging dataset: Median progression-free survival of 8.9 months in EGFR. exon 21 L858R patients who completed six cycles of LP-300 (n=9), compared. with 8.4 months across the overall L858R cohort , and a hazard. clinical benefit rate and tumor reduction in more than ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGIX","R","BK4604","BK4555","03160","ARTY","QTOC","BK4139","AIPO","CHAT","TM","BK4022","VTHR","LTRN","BK4081","VGT","BK4585","BK4099","EMA","BK4232","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659914610","title":"Sasseur REIT's 1HFY2026 DPU up 10% y-o-y to 3.366 cents","url":"https://stock-news.laohu8.com/highlight/detail?id=2659914610","media":"Teo Zheng Long","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659914610?lang=en_us&edition=fundamental","pubTime":"2026-08-13 23:52","pubTimestamp":1786636378,"startTime":"0","endTime":"0","summary":"Weighted average cost of debt declined to 3.7% as at June 30, compared to 4.4% as at Dec 31, 2025.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"edge_highlight","url":"https://www.theedgesingapore.com/capital/results/sasseur-reits-1hfy2026-dpu-10-y-o-y-3366-cents?utm_source=Blog&utm_medium=RSS&utm_campaign=Tiger_Brokers_app_RSS","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.theedgesingapore.com/capital/results/sasseur-reits-1hfy2026-dpu-10-y-o-y-3366-cents?utm_source=Blog&utm_medium=RSS&utm_campaign=Tiger_Brokers_app_RSS","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"edge_highlight","symbols":["RJMG","IVRA","REIX","BK6142","8C8U.SI","BK4127","IQRA","DPU","MDIV","YLDW","BK4081","SRU.SI","DFRA","JJJ.SI","SRT.SI","GLS.SI","CLR.SI","EMA","REIT","RNTY","BPRE","PSCF","CFA.SI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659155751","title":"Press Release: Zenas BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2659155751","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659155751?lang=en_us&edition=fundamental","pubTime":"2026-08-13 19:00","pubTimestamp":1786618800,"startTime":"0","endTime":"0","summary":"Company's Biologics License Application  for obexelimab for the. treatment of Immunoglobulin G4-Related Disease : The BLA has a. Prescription Drug User Fee Act  target action date of May 27,2027. Zenas expects to submit a Marketing Authorization Application . to the European Medicines Agency  in the second half of 2026.-- Positive results from the Phase 3 INDIGO registrational trial of. obexelimab for the treatment of IgG4-RD presented at EULAR and published. in NEJM in June 2026: Additional data from the INDIGO trial presented at","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4215","SLE","BK4081","BK4585","BK4588","EMA","BK4077","MAA","ZBIO","SPRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659138453","title":"Press Release: Valneva Reports Half Year 2026 Financial Results and Provides Corporate Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2659138453","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659138453?lang=en_us&edition=fundamental","pubTime":"2026-08-13 13:00","pubTimestamp":1786597200,"startTime":"0","endTime":"0","summary":"-- In-line with expectations; full-year guidance of EUR135 -150. -- Solid cash position of EUR121.5 million as of end June 2026. -- Reflects disciplined cash management and proceeds from the recent. -- Restructuring program implemented with positive P&L and cash flow. impacts expected in the second half of the year and beyond. -- Regulatory decisions for Lyme disease vaccine candidate expected in the. -- Pfizer remains optimistic about obtaining registration for the. sales, compared with EUR97.6 million and EUR91.0 million, respectively,in the first half of 2025. The year-over-year decrease primarily reflects. the planned wind-down of third-party sales (down EUR10.5 million versus. the first half of 2025) and the expected phasing of product sales,EUR109.7 million as of December 31, 2025. This strong cash position. reflects the positive impact of restructuring initiatives, disciplined. cash management and EUR37 million in gross proceeds from the successful. in the first half of 2025, re","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4022","BK4139","VALN","BK4232","CHIM","BK4539","EMA","BK4081","R"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659907259","title":"Press Release: Longeveron Announces 2026 Second Quarter Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2659907259","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659907259?lang=en_us&edition=fundamental","pubTime":"2026-08-13 04:05","pubTimestamp":1786565100,"startTime":"0","endTime":"0","summary":"-- On track for September 2026 top-line results from Phase 2b clinical trial.  evaluating laromestrocel as a potential adjunct treatment for. hypoplastic left heart syndrome , a rare pediatric disease and. -- Longeveron selected as a Finalist and Milestone 2 Awardee for the XPRIZE. Healthspan competition based on published clinical trial results which. indicated laromestrocel increased 6-minute walk distance in patients with. -- Three new independent Directors join Longeveron's Board of Directors. laromestrocel as a potential adjunct therapy for HLHS are anticipated in. -- In May, the Company announced that the U.S. Food and Drug Administration.  held a Type C meeting in late March 2026 focused on the ELPIS II. Phase 2b clinical trial and upcoming data readout.-- Also in May, the Company announced that the independent Data Monitoring. Committee  completed its final prespecified data review for ELPIS II. Phase 2b clinical trial . The DMC performed a risk-benefit. assessment, indicated n","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4022","AD","EMA","NVIB","BK4081","IND","MEDX","GDOC","R","BK4139","HYLG","BK4132","LGVN","BK4189","IDNA","DMC","BK4232"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659904433","title":"Press Release: Bernhard Capital Partners Completes Acquisition of New Mexico Gas Company","url":"https://stock-news.laohu8.com/highlight/detail?id=2659904433","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659904433?lang=en_us&edition=fundamental","pubTime":"2026-08-13 02:04","pubTimestamp":1786557840,"startTime":"0","endTime":"0","summary":"BATON ROUGE, La., Aug. 12, 2026 /PRNewswire/ -- Bernhard Capital Partners (\"Bernhard\"), an infrastructure and services-focused private markets investment firm, announced today that it has closed on it","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ERX","VDE","BK4585","EMA","BK4588","BK4081"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658908917","title":"Milestone Pharmaceuticals Announces Second Quarter 2026 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2658908917","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658908917?lang=en_us&edition=fundamental","pubTime":"2026-08-12 19:08","pubTimestamp":1786532880,"startTime":"0","endTime":"0","summary":"Over 50% of commercially insured lives in the U.S., representing a recent and significant increase, now have coverage for CARDAMYST (etripamil) nasal spray Phase 3 registrational trial of etripamil fo","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/12/3343531/0/en/milestone-pharmaceuticals-announces-second-quarter-2026-financial-results-and-provides-corporate-update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1559883803.SGD","LU0566484027.USD","BK4129","AV","ECG","EMA","BK4081"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658794159","title":"Press Release: Pharvaris Reports Second Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2658794159","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658794159?lang=en_us&edition=fundamental","pubTime":"2026-08-12 18:50","pubTimestamp":1786531800,"startTime":"0","endTime":"0","summary":"-- Topline data from CHAPTER-3, a pivotal Phase 3 study of deucrictibant XR. for the prophylaxis of HAE attacks, expected in 3Q2026. -- Deucrictibant IR NDA under review by the FDA with PDUFA date of April 23,-- Enrollment ongoing in CREAATE, a pivotal study of deucrictibant for the. -- Strong financial position with cash and cash equivalents of EUR318. is a randomized, double-blind, placebo-controlled Phase 3 study of orally. prophylaxis against angioedema attacks in adults and adolescents (12. years and older) with HAE. Eighty-five participants were enrolled and. randomized in a 2:1 ratio to receive deucrictibant XR , the. Pharvaris expects to announce topline data from CHAPTER-3 in the third. is a long-term, open-label extension study of orally administered. attacks. The goal of the study is to evaluate the long-term safety and","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0205193047.USD","LU0106261612.USD","HAE","IE00B19Z6F94.USD","IR","IE00B64QTZ34.USD","LU0205194284.USD","LU0256863811.USD","BK4161","EMA","LU0124384867.USD","IE00BLDYK493.USD","IE0034390439.USD","LU0256863902.USD","LU1169589451.USD","SG9999001440.SGD","SPRE","LU0012050646.USD","LU1169590202.USD","BK4588","MAA","BK4198","BK4081","LU1978683503.SGD","BK4215","BK4007","BK4585","LU0417517546.SGD","PHVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658914350","title":"Analysts Are Bullish on These Utilities Stocks: Emera (EMA), Edenor SA (EDN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2658914350","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658914350?lang=en_us&edition=fundamental","pubTime":"2026-08-12 00:00","pubTimestamp":1786464032,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Utilities sector as 2 analysts just weighed in on Emera (EMA) and Edenor SA (EDN) with bullish sentimen...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-utilities-stocks-emera-ema-edenor-sa-edn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-utilities-stocks-emera-ema-edenor-sa-edn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EDN","EMA","BK4081","BK4563"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658990336","title":"Press Release: Theriva(TM) Biologics Reports Second Quarter 2026 Operational Highlights and Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2658990336","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658990336?lang=en_us&edition=fundamental","pubTime":"2026-08-11 20:00","pubTimestamp":1786449600,"startTime":"0","endTime":"0","summary":"Phase 2a clinical trial entitled \"A Phase IIa, single-arm, single-center,-- The VIRAGE2 study design incorporates feedback from both the. European Medicines Agency  and the U.S. Food and Drug. VIRAGE Phase 2b trial in metastatic PDAC patients treated with 2. repeated dosing of VCN-01 may provide additional clinical benefit.-- The VIRAGE2 trial will evaluate the safety and feasibility of. administering at least 3 doses of VCN-01 given approximately 2. The trial is expected to enroll 6 evaluable patients. Results from. the VIRAGE2 study will inform the VCN-01 dosing regimen for","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4604","NVIB","BK4555","GDOC","03160","LU0210528500.USD","BK4139","LU0053666078.USD","HYLG","TM","L","LU2487616109.SGD","MEDX","TOVX","BK4081","BK4107","BK4585","BK4099","EMA","IDNA","BK4588"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":1,"totalSize":200,"code":"91000000","status":"200"}]}}